News

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...
Novavax’s COVID-19 vaccine shows lower side effects vs. Pfizer-BioNTech’s
Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...
AOL14d
FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS
The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's (NVAX) COVID-19 vaccine this week, but that deadline has passed with no clarity on ...
WXII 12 NEWS14d
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The U.S. Food and Drug Administration has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on ...
HealthDay on MSN8d
FDA Delays Final Approval of Novavax COVID-19 Vaccine
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...
Novavax’s Covid vaccine delayed in FDA review
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
US drug regulator delays Novavax COVID vaccine approval
The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...